Voyager Therapeutics Inc (VYGR) Quote

Is this good or bad? Think it found a bottom.
We are looking to get in but not sure where

VYGR, new 52=week low

VYGR under $6

VYGR under $10

Todays action??

6.76 for support if not exit up to 7.36 is the zone to watch. Careful on stop loss. If 6.76 doesn’t hold see you at 5.77 on the short side

Nice dip here 6.90 grab a few

you might be right on KRRO but I dont know their team and the valuation seems lofty to me given its muuuch earlier than WVE

$7.90 look at KRRO at $96 +142% Looking better …maybe…
Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the joint steering committee with its collaborator Neurocrine Biosciences, Inc. has selected a development candidate in a gene therapy program for the potential treatment of an undisclosed neurological disease. The candidate leverages an intravenously administered, blood-brain barrier-penetrant, novel capsid derived from Voyager’s TRACER™ capsid discovery platform.
Selection of the development candidate triggered a $3 million milestone payment to Voyager, which the Company expects to receive in the fourth quarter of 2024. Voyager is eligible to receive additional future development and commercialization milestone payments based on the further advancement of this program.

“This is the third development candidate nominated under Voyager’s collaborations with Neurocrine, following nominations for Friedreich’s ataxia and for GBA1 Parkinson’s disease and other GBA1-mediated diseases,” said Alfred W. Sandrock, Jr., M.D., Ph.D., Chief Executive Officer of Voyager. “These partnered programs provide multiple opportunities for success and complement our wholly-owned pipeline, including our SOD1 ALS gene therapy program, which is advancing towards an expected IND in mid-2025.”

This program is being developed under the 2023 strategic collaboration agreement between Voyager and Neurocrine Biosciences for research, development, manufacture, and commercialization of certain AAV gene therapy products for programs targeting Parkinson’s disease and other GBA1-mediated diseases and three other undisclosed programs. Under the terms of the 2023 collaboration agreement, for each of the three undisclosed programs, Voyager is eligible to receive up to $175 million in potential development milestone payments plus substantial potential commercial milestone payments, as well as tiered high single-digit to mid-teens royalties on U.S. net sales and mid-single-digit to low double-digit royalties on ex-U.S. net sales. Neurocrine Biosciences will fund the development of each program.

About the TRACER™ Capsid Discovery Platform

Voyager’s TRACER™ (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) capsid discovery platform is a broadly applicable, RNA-based screening platform that enables rapid discovery of novel AAV capsids to enable gene therapy. Voyager has leveraged TRACER to create multiple families of novel capsids that, following intravenous delivery in preclinical studies, harness the extensive vasculature of the central nervous system (CNS) to cross the blood-brain barrier and transduce a broad range of CNS regions and cell types. In cross-species preclinical studies (rodents and multiple non-human primate species), intravenous delivery of TRACER-generated capsids resulted in widespread payload expression across the CNS at relatively low doses, enabling selection of multiple development candidates in Voyager’s wholly-owned and partnered gene therapy programs for neurologic diseases.

About Voyager Therapeutics

Voyager Therapeutics, Inc. (Nasdaq: VYGR) is a biotechnology company dedicated to leveraging the power of human genetics to modify the course of – and ultimately cure – neurological diseases. Our pipeline includes programs for Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple other diseases of the central nervous system. Many of our programs are derived from our TRACER™ AAV capsid discovery platform, which we have used to generate novel capsids and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. Some of our programs are wholly owned, and some are advancing with partners including Alexion, AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc.; and Sangamo Therapeutics, Inc. For more information, visit www.voyagertherapeutics.com.

Voyager Therapeutics® is a registered trademark, an

will they figure it out now?

starter
has 3.5bn in milestones and multiple partners.
Maybe.... just maaaaaybe their AAV capsid platform works too. Pfizer, Abbvie and Novartis on board...
Gene therapy wizards at Novartis were ready to put 100mn upfront (20 equity 80 cash) and 1.7bn in milestones on the table.

VYGR new 52=week low

Truly a mofo’ing gift under $10.
This was calling for $40/share not too long ago

VYGR under $10

VYGR

will be bought out. So many milestones to be paid.

VYGR under $10

Target price $30 by Wainwright - was only a matter of time - the analysts were completely wrong and blown away by both the revenues and eps last quarter.

Holy smokes - $3 EPS on HUGE revenue increase: https://www.otcmarkets.com/stock/VYGR/financials

Insider dumping=easy short.

VYGR: Insider dumping --- at the Firm, & their Homeboys & Homegirls. SAD!!! (TRUTH be told.)

Is the next pump and dump? Asking for a friend…

As of December 31, 2023, our cash, cash equivalents, and marketable securities were $230.9 million. Based upon our current operating plan, we expect that our existing cash, cash equivalents, and marketable securities at December 31, 2023, together with the $80.0 million upfront payment received in January 2024 in connection with the 2023 Novartis Collaboration Agreement, the $20.0 million in proceeds from Novartis’ stock purchase, and the $93.5 million in net proceeds received from our public offering in January 2024, along with amounts expected to be received as reimbursement for development costs under our collaboration and license agreements with Neurocrine and Novartis, certain near term milestones, and interest income, to be sufficient to meet our planned operating expenses and capital expenditure requirements into 2027.

incredible - blows away the analysts

VYGR: Big news!! HUGE NET INCOME, vs. net LOSS of last report.
https://finance.yahoo.com/news/voyager-therapeutics-inc-vygr-announces-214155031.html

We have 500 shares in each of 2 accounts. Both are profitable, entry ~ $4 in the IRA, LTCG. XBI, IBB negative today. No worries, but Fed bears watching, eh?

News? Bankruptcy imminent. Sheeple woke up from COVID scare and know this and med companies are a sham

Off > $3 from your post 2 weeks later. Trading at $7.12 at 1:50 pm today. News? None that I see.

VYGR 10.93 NHOD

Yeah! Nice! :)

VYGR avg 9.51 just sold 10.51 (+$1/share) and its still going

i am in avg 9.54 and its 8.95

SMH

that news is yuge

but they sold it off

SMH

correction HNY

not HPN

lol

HPN $VYGR LOOKIN GOOD ON NEWS https://dilutiontracker.com/app/search/VYGR?a=dbb88c

oday 10:46AM
VYGR Stock Alert: The $1.2 Billion Reason Voyager Therapeutics Is Up Today
(InvestorPlace) +24.32%
10:36AM
Novartis Sweetens Its Deal With Voyager, And VYGR Stock Up 29% Flashes A Bullish Sign
(Investor's Business Daily)
07:36AM
UPDATE 2-Novartis signs gene therapy deal with Voyager for $100 mln upfront
(Reuters)
07:14AM
Voyager Therapeutics shares jump after $1.2 billion deal with Novartis
(Reuters)
07:14AM
Novartis signs gene therapy deal with Voyager for $100 mln upfront
(Reuters)

NEWS
Voyager Therapeutics Enters Capsid License Agreement and Strategic Collaboration with Novartis to Advance Novel Gene Therapies
- Collaboration with gene therapy leader Novartis aims to discover and develop new approaches for Huntington’s disease and spinal muscular atrophy -

- Voyager to receive up-front consideration of $100 million and is eligible to receive milestone payments and tiered royalties -

LEXINGTON, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced a strategic collaboration and capsid license agreement with Novartis Pharma AG, a subsidiary of Novartis AG (NYSE: NVS) to advance potential gene therapies for Huntington’s disease (HD) and spinal muscular atrophy (SMA). Voyager will provide Novartis a target-exclusive license to access Voyager’s TRACER™ capsids and other intellectual property for the respective diseases, and Voyager and Novartis will collaborate to advance a preclinical gene therapy candidate for HD.

“We are thrilled to expand our existing relationship with Novartis, a global leader in the gene therapy field,” said Alfred W. Sandrock, Jr., M.D., Ph.D., Chief Executive Officer of Voyager. “Combining the proven capabilities of Novartis in gene therapy development and commercialization with Voyager’s next-generation TRACER capsids and payloads could enable the advancement of important new therapies for patients. In addition, the consideration Voyager will receive from this collaboration will strengthen our balance sheet and extend our runway into mid-2026.”

“We look forward to broadening our work with Voyager to help bring forward novel, high-impact gene therapies with the potential to improve the lives of patients affected by severe neurologic conditions,” said Fiona Marshall, President of Biomedical Research at Novartis. “We believe Voyager’s TRACER capsids hold promise for enabling next-generation gene therapies for diseases of the central nervous system, aligning well with our deep neuroscience expertise and gene therapy leadership at Novartis.”

Novartis previously exercised options to license novel capsids generated from Voyager’s TRACER capsid discovery platform for use in gene therapy programs against two undisclosed neurological disease targets.

Collaboration Details and Financial Terms
Under the terms of the agreement, Novartis has agreed to pay Voyager $100 million of consideration up front, including a $20 million purchase of newly issued equity in Voyager. Voyager is eligible to receive up to $1.2 billion in preclinical, development, regulatory and sales milestones, as well as tiered royalties on global net sales of products incorporating Voyager’s TRACER capsids. Novartis will obtain target-exclusive access to Voyager’s TRACER capsids related to SMA for the duration of the agreement and will be responsible for all development and commercialization. Novartis will also receive worldwide rights to Voyager’s AAV gene therapy for HD, leveraging Voyager’s TRACER capsids and proprietary payloads. Voyager will be responsible for preclinical advancement and Novartis will be responsible for all clinical development and commercialization for the HD program.

Chestnut Partners served as exclusive financial advisor to Voyager on this transaction.

About the TRACER™ Capsid Discovery Platform
Voyager’s TRACER™ (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) capsid discovery platform is a broadly applicable, RNA-based screening platform that enables rapid discovery of AAV capsids with robust penetration of the blood-brain barrier and enhanced central nervous system (CNS) tropism in multiple species, including non-human primates (NHPs). In preclinical studies, TRACER generated capsids have demonstrated widespread gene expression in the CNS compared to conventional AAV capsids as well as cell- and tissue-specific transduction, including to areas of the brain that have been traditionally difficult to reach, while de-targeting the liver and dorsal root ganglia. As part of its external partnership strategy, Voyager has established multiple collaboration agreements providing access to its next-generation TRACER capsids to potentially enable its partners’ gene therapy programs to treat a variety of diseases.

About Voyager Therapeutics
Voyager Therapeutics, Inc. (Nasdaq: VYGR) is a biotechnology company dedicated to leveraging the power of human genetics to modify the course of – and ultimately cure – neurological diseases. Our pipeline includes programs for Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple other diseases of the central nervous system. Many of our programs are derived from our TRACER™ AAV capsid discovery platform, which we have used to generate novel capsids and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. Some of our programs are wholly owned, and some are advancing with partners including Alexion, AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc.; and Sangamo Therapeutics, Inc. For more information, visit www.voyagertherapeutics.com.

Voyager Therapeutics® is a registered trademark, and TRACER™ is a trademark, of Voyager Therapeutics, Inc.

Forward-Looking Statements

Too bad they killed this one. Should have gone to $25-40 easily

I’ll be watching $9.05 to $7.85 very closely
#GLTA
#ELGORDODAMUS
$VYGR

Eat a Dk vygr. Can’t stay hard huh?

Nice run on $VYGR
$5.68 to $10.77
In 4 month not a bad trade..
#ELGORDODAMUS

Entice new guppies. You know how we do :)

8.25 hmmmm

indeed .....aGREED

Gap up! Trap that new young blood LOL

$VYGR NEWS https://finance.yahoo.com/news/neurocrine-biosciences-voyager-therapeutics-enter-120000143.html

It’s about to get really interesting on this Board
Let’s go $VYGR
#ELGORDODAMUS

Up like an escalator down like an elevator.
Good stuff

$9.74
new 52wh

OK in for $2.86

VYGR. filled the gap at $3.60

Soon that will be 1 or more years ???